|
注册号: Registration number: |
ChiCTR2500111958 |
|
最近更新日期: Date of Last Refreshed on: |
2025-11-07 16:39:25 |
|
注册时间: Date of Registration: |
2025-11-07 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
经鼻高流量在ERCP衰弱患者中的应用:一项随机对照研究 |
|
Public title: |
Application of nasal high flow in frailty patients with ERCP: a randomized controlled study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
经鼻高流量在ERCP衰弱患者中的应用:一项随机对照研究 |
|
Scientific title: |
Application of nasal high flow in frailty patients with ERCP: a randomized controlled study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
韩香杰 |
研究负责人: |
王晖 |
|
Applicant: |
Han Xiangjie |
Study leader: |
Wang Hui |
|
申请注册联系人电话: Applicant telephone: |
+86 131 0002 1179 |
研究负责人电话:
Study leader's |
+86 131 0002 1179 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
hanmedical@163.com |
研究负责人电子邮件: Study leader's E-mail: |
hanmedical@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市朝阳区工人体育场南路8号北京朝阳医院 |
研究负责人通讯地址: |
北京市朝阳区工人体育场南路8号北京朝阳医院 |
|
Applicant address: |
Beijing Chaoyang Hospital, No. 8 Workers' Stadium South Road, Chaoyang District, Beijing |
Study leader's address: |
Beijing Chaoyang Hospital, No. 8 Workers' Stadium South Road, Chaoyang District, Beijing |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
北京朝阳医院 |
||
|
Applicant's institution: |
Beijing Chaoyang Hospital |
||
|
研究负责人所在单位: |
北京朝阳医院 |
||
|
Affiliation of the Leader: |
Beijing Chaoyang Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2023-科-746 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
首都医科大学附属北京朝阳医院伦理委员会 |
||
|
Name of the ethic committee: |
Beijing Chaoyang Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-12-22 00:00:00 | ||
|
伦理委员会联系人: |
吕亚丽 |
||
|
Contact Name of the ethic committee: |
Lv Yali |
||
|
伦理委员会联系地址: |
北京市朝阳区工人体育场南路8号北京朝阳医院 |
||
|
Contact Address of the ethic committee: |
Beijing Chaoyang Hospital, No. 8 Workers' Stadium South Road, Chaoyang District, Beijing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 8523 1484 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
北京朝阳医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Beijing Chaoyang Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市朝阳区工人体育场南路8号北京朝阳医院 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Beijing Chaoyang Hospital, No. 8 Workers' Stadium South Road, Chaoyang District, Beijing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
无 |
||||||||||||||||||||||
|
Source(s) of funding: |
none |
||||||||||||||||||||||
|
研究疾病: |
呼吸衰弱 |
||||||||||||||||||||||
|
Target disease: |
Respiratory weakness |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
探究经鼻高流量吸氧对于ERCP检查术中的衰弱患者术后恢复质量的影响,为衰弱患者无痛全麻方案以及无痛全麻适用范围提供参考,降低患者术中及术后并发症的发生率,提高患者术后苏醒质量及恢复质量以及患者全麻安全性和舒适性。 |
||||||||||||||||||||||
|
Objectives of Study: |
To explore the effect of nasal high-flow oxygen on the postoperative recovery quality of frail patients during ERCP examination, to provide a reference for the painless general anesthesia regimen for frail patients and the scope of application of painless general anesthesia, to reduce the incidence of intraoperative and postoperative complications, to improve the quality of postoperative recovery and recovery, and the safety and comfort of patients under general anesthesia. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.鼻出血史,丙泊酚过敏,HFNC禁忌症者(相对禁忌:重度I型呼衰;通气功能障碍;pH<7.30; 2.矛盾呼吸; 3.气道保护功能差,有误吸高危风险; 4.血流动力学不稳定需要用血管活性药物; 5.面部或上呼吸道手术不能佩戴HFNC者; 6..鼻腔堵塞严重;HFNC不耐受。 7.绝对禁忌症:心跳呼吸骤停,需紧急气管插管有创机械通气者; 8.自主呼吸微弱、昏迷;极重度I型呼衰;通气功能障碍pH<7.25;无法或拒绝进行研究知情同意签署) |
||||||||||||||||||||||
|
Exclusion criteria: |
1. History of epistaxis, propofol allergy, or contraindications to HFNC (relative contraindications: severe type I respiratory failure; ventilatory dysfunction; pH < 7.30); 2. Paradoxical breathing; 3. Poor airway protection with high risk of aspiration; 4. Haemodynamic instability requiring vasoactive medications; 5. Facial or upper airway surgery precluding HFNC use; 6. Severe nasal obstruction; intolerance to HFNC. 7. Absolute contraindications: cardiac arrest requiring emergency tracheal intubation and invasive mechanical ventilation; 8. Weak spontaneous breathing, coma; extremely severe type I respiratory failure; ventilatory dysfunction with pH < 7.25; inability or refusal to sign informed consent for the study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-05-01 00:00:00至 To 2023-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2023-05-31 00:00:00 至 To 2023-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
采用随机数字表随机化分组(SPSS生成伪随机数——可重现序列的具有随机数统计学特征的数字表) |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Patients were randomly allocated into groups using a random number table generated by SPSS, which produced a reproducible sequence of pseudo-random numbers with statistical characteristics of randomness. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
本研究为单盲对照研究,只有研究者知道分组信息,外科医生、患者、随访人员、数据分析师均不清楚患者所在分组。 |
|
Blinding: |
This study was designed as a single-blind controlled trial. Only the investigators were aware of the group assignments, while the surgeons, patients, follow-up personnel, and data analysts were blinded to the allocation. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
临床试验公共管理平台(http://www.medresman.org.cn/uc/projectsh/projectlistauthor.aspx);共享时间:2024-06-31 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
ResMan (http://www.medresman.org.cn/uc/projectsh/projectlistauthor.aspx); Data sharing date: June 31, 2024 |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
采用病例记录表对患者数据进行采集,使用EDC对数据进行管理 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Patient data were collected using case recorded forms and managed using EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |